XSXin Shu

Xin Shu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xin Shu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Explainable AI-Derived Spatial Pathological Features of Tumor, Necrosis, and Lymphocytes Identify Key Histological Signatures for Residual Cancer Burden Assessment in Breast Cancer

    by Xin Shu, Fan Wang, Tiancheng Zhao, Yun Zhang, Yao Zhou, Liu Yang, Xiujuan Xiong, Libin Deng

    Background: Conventional histopathological assessment of residual cancer burden (RCB) following neoadjuvant therapy for breast cancer relies on manual visual evaluation, lacking objective quantification of spatial interactions among tumor, necrosis, and lymphocyte compartments. This limits prognostic accuracy and impedes personalized treatment stratification. Methods: We developed an explainable AI framework to segment three tissue compartments from H&E patches and constructed 11 spatial pathological features. This two-center study included 347 post-neoadjuvant patients (182 development, 165 external validation) plus 843 TCGA-BRCA cases for exploratory external validation. VGG-16, ResNet-50, and ViT-Base were evaluated; multiple instance learning identified target regions for feature construction. Six machine learning models with LASSO-selected features were interpreted via SHAP and Grad-CAM, with TCGA-BRCA serving as an exploratory external cohort. Results: VGG-16 achieved optimal segmentation (all AUCs > 0.90). In the external validation set, XGBoost achieved AUCs of 0.781 for Task 1 (RCB-0 vs. RCB-1+2+3) and 0.896 for Task 2 (RCB-0+1 vs. RCB-2+3). For Task 3 (RCB-0+1+2 vs. RCB-3), the model achieved an AUC of 1.000, with complete separation between groups. SHAP analysis revealed that the Necrotic Tumor Mixed Cluster (T+N) was the dominant indicator for Task 1 (mean |SHAP| = 0.439) and Task 2 (mean |SHAP| = 0.803), while the Pure Necrotic-Rich Zone (N-only) was the dominant indicator for Task 3 (mean |SHAP| = 1.967). In exploratory TCGA association analyses, the Pure Tumor-Rich Zone (T-only) exhibited a positive correlation (ρ = 0.706, p < 0.001; T-only is a feature used to derive this model-estimated RCB-like score), whereas the Lymphocyte-Infiltrated Necrotic Zone (N+L) showed a negative correlation (ρ = −0.407, p < 0.001) with the model-estimated RCB-like score, linking tumor-rich zones to immunosuppression and lymphocyte-infiltrated necrotic zones to immune activation. Conclusions: Our spatial pathological features effectively estimate RCB, with T+N and N-only as the predominant SHAP-identified indicators across the three tasks. Exploratory analyses further suggest that tumor-rich and lymphocyte-infiltrated necrotic zones correlate with opposing immune phenotypes, supporting personalized breast cancer management.

  • Open Access

    Prediction of neoadjuvant therapy response in breast cancer based on interpretable artificial intelligence

    by Yao Zhou, Xin Shu, Fan Wang, Hui Xu, Hong-Qun Tang, Hao Fang, Jing Huang, Yi-Wei Wang, Hong-Liang Ji, Shi-Wei Zhang, et al.

    Background: To develop an AI-based predictive model for neoadjuvant therapy (NAT) efficacy in breast cancer, we integrated multimodal data and analyzed tumor microenvironment (TME) features to provide interpretability. Methods: We retrospectively analyzed H&E-stained whole-slide images (WSIs) from a multicenter cohort of breast cancer patients receiving NAT to develop an AI predictive model. The cohort was stratified into training, test, internal validation, and external validation sets. Feature extraction used UNI and classification employed a multiple instance learning (MIL) framework. Model performance was evaluated via ROC curve analysis (AUC, precision, specificity, recall). Molecular mechanisms underlying model predictions were explored using TCGA multimodal data, integrating differential gene expression profiling with pathway enrichment analysis (GO, KEGG). TME component correlations with model scores were also investigated. Results: The AI model demonstrated robust discriminative capacity across three residual cancer burden (RCB)-based classification tasks in 826 patients from two centers, achieving peak performance in subtask 2 (NAT-sensitive: RCB 0–1 vs. NAT-resistant: RCB 2–3). For subtask 2, AUCs were 0.901 (training), 0.858 (test), 0.808 (internal validation), and 0.819 (external validation). Molecular analysis linked the model’s predictive efficacy to tumor cell cycle processes. TME analysis revealed positive correlations between model scores and activated immune cells (M0/M1 macrophages, dendritic cells), and negative correlations with inhibitory cells (M2 macrophages, resting mast cells). Crucially, the model’s predictive scores were closely related to tumor-infiltrating lymphocytes (TILs), with spatial colocalization observed between classification weights and TILs distribution. Significant differences in TILs levels occurred across model score strata, validating the model’s biological plausibility in predicting NAT response mechanisms. Conclusion: We developed an interpretable AI model that predicts response to neoadjuvant therapy in breast cancer using H&E slides. The model’s predictions are biologically interpretable, correlating with TME dynamics and spatial TIL patterns, offering a novel strategy for personalizing NAT treatment strategies.


  • Open Access

    Transcriptome Changes of Hematopoietic Stem and Progenitor Cells in the Peripheral Blood of COVID-19 Patients by scRNA-seq

    by Jinfu Zhang, Xin Shu, Rong Deng, Zihao Yang, Manling Shu, Xiangying Ou, Xuan Zhang, Zhenyu Wu, Huihong Zeng, Lijian Shao

    Coronavirus disease 2019 (COVID-19) threatens public health all over the world. It is well-accepted that the immune cells in peripheral blood are widely involved in the pathological process of COVID-19. However, hematopoietic stem and progenitor cells (HSPCs), as the main source of peripheral immune cells, have not been well studied during COVID-19 infection. We comprehensively revealed the transcriptome changes of peripheral blood HSPCs after COVID-19 infection and vaccination by single-cell RNA-seq. Compared with healthy individuals, the proportion of HSPCs in COVID-19 patients significantly increased. The increase in the proportion of HSPCs might be partly attributed to the enhancement of the HSPCs proliferation upon COVID-19 infection. However, the stemness damage of HSPCs is reflected by the decrease of differentiation signal, which can be used as a potential specific indicator of the severity and duration of COVID-19 infection. Type I interferon (IFN-I) and translation signals in HSPCs were mostly activated and inhibited after COVID-19 infection, respectively. In addition, the response of COVID-19 vaccination to the body is mild, while the secondary vaccination strengthens the immune response of primary vaccination. In conclusion, our study provides new insights into understanding the immune mechanism of COVID-19 infection.